OCT 26, 2012
Avedro has exclusively licensed EyeGate Pharma’s iontophoresis patents in the field of corneal collagen cross-linking, according to a press release.
Iontophoresis uses a small electric charge to deliver a medicine or other chemical through the skin. In cross-linking, it has the potential to deliver riboflavin into the cornea without removing the epithelium.
“This license allows Avedro the rights to pursue any use of EyeGate’s systems in the field of corneal collagen cross-linking,” said David Muller, PhD, CEO of Avedro. “Iontophoresis is a delivery approach, among others, that we intend to investigate to determine if it may offer any additional benefits to the excellent clinical results we have achieved with ParaCel, our current transepithelial cross-linking formulation.”